PLSE - NASDAQ
Pulse Biosciences, Inc.
$24.99
+1.3%Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
At a Glance
Live SnapshotPulse Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Pulse Biosciences, Inc. Cash Flow Statement
PLSE • NASDAQ
| Pulse Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||
-72.8M | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M | -47M | -37.5M | -25.6M | -9.5M | -2.8M | -474.9K | |
1.1M | 1.2M | 1.2M | 1.4M | 1.1M | 1.1M | 1.2M | 1.3M | 1M | 759K | 717K | 200.6K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28K | 26K | -870K | -1.7M | 0.0 | |
21.5M | 13.6M | 7.2M | 5.2M | 14.6M | 10.1M | 11.3M | 12.3M | 10.9M | 870K | 402.1K | 0.0 | |
1.2M | 6K | 13K | 8.7M | 13K | 116K | -521K | -112K | 2.1M | 874K | 1.7M | -18.9K | |
-5M | 2.5M | 768K | -3.7M | -6.2M | 3.2M | 860K | 113K | 408K | -166K | -1.6M | 120K | |
-54.1M | -36.3M | -33M | -47M | -54.1M | -35.4M | -34.2M | -23.9M | -11.1M | -8.1M | -3.3M | -173.1K | |
INVESTING ACTIVITIES | ||||||||||||
-315K | -125K | -121K | -401K | -437K | -441K | -608K | -276K | -2.6M | -64K | -86K | -78.9K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -10.5M | (9.5M) | (0.0) | (0.0) | (64K) | (0.0) | (1.7K) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -29M | -78M | -40.3M | -43.6M | -19.1M | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 8M | 39.5M | 68.5M | 66.7M | 23.1M | 4.8M | 0.0 | 0.0 | |
-20K | 0.0 | 0.0 | 0.0 | 0.0 | 10.5M | -9.5M | 26.4M | -20.4M | -64K | 0.0 | 0.0 | |
-335K | -125K | -121K | -401K | (7.6M) | (10M) | -10.1M | (26.1M) | -23M | -14.4M | -86K | -77.1K | |
FINANCING ACTIVITIES | ||||||||||||
17.2M | 59.6M | 16.4M | 14.9M | 56.7M | 29.4M | 0.0 | 44.8M | 34.8M | 20.9M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 65M | 407K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -613K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 50.5M | -6K | 75K | 62.5M | 1.5M | 82K | 710K | 539K | 0.0 | 0.0 | 12.3M | |
17.2M | 110.1M | 16.4M | 79.9M | 62.7M | 30.9M | 82K | 45.5M | 35.4M | 20.9M | 0.0 | 12.3M | |
CASH FLOW SUMMARY | ||||||||||||
-37.3M | 73.7M | -16.8M | 32.5M | 16.2M | 5.6M | -44.2M | 47.7M | 1.3M | -1.5M | -3.4M | 12M | |
118M | 44.4M | 61.1M | 28.6M | 12.5M | 6.9M | 51.1M | 3.4M | 2.1M | 3.6M | 7M | 0.0 | |
80.7M | 118M | 44.4M | 61.1M | 28.6M | 12.5M | 6.9M | 51.1M | 3.4M | 2.1M | 3.6M | 12M | |
-54.4M | -36.5M | -33.2M | -47.4M | -54.5M | -35.8M | -34.8M | -24.2M | -13.6M | -8.1M | -3.4M | -252K |
SEC Filings
PLSE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | May 11, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 |
Related Guides
Continue your PLSE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.